We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
- Recent DXCM Stock Price: $83.83
- Yearly Gain for DXCM stock: -34.42%
- Market Cap for DXCM stock: $32.90B
- P/E Ratio for DXCM stock: 173.059
Will DXCM's stock price go up? Is there an accurate DXCM stock forecast available?
TipRanks.com reports that Dexcom currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $100.27. The target pricing ranges from a high DXCM forecast of $125.00 down to a low forecast of $83.00. Dexcom (DXCM)’s last closing stock price was $83.83 which would put the average price target at 19.61% upside.
In addition, TradingView issued a Buy rating for DXCM stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on DXCM stock.
Other analysts covering DXCM include:
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 100 on 4 days ago
- Steven Lichtman of Oppenheimer issued a Buy rating with the price target of $ 105 on 4 days ago
- Larry Biegelsen of Wells Fargo issued a Buy rating with the price target of $ 102 on 4 days ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 83 on 4 days ago
If you are wondering if DXCM is a good stock to buy, here are 3rd party ratings for DXCM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 37% (93 out of 251)
What is the sentiment on the street regarding Dexcom? (Current ratings compiled by TipRanks.com)
- News Sentiment for DXCM stock: Very Bullish
- Blogger Consensus for DXCM stock: Bullish
- Media Buzz for DXCM stock: High
- Insider Signal for DXCM stock: ―
- Investor Sentiment for DXCM stock: Positive
- Hedge Fund signal for DXCM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on DXCM stock including scouring the social networks like DXCM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DXCM stock chart >>
Summary: Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
- Recent EW Stock Price: $99.45
- Yearly Gain for EW stock: -12.21%
- Market Cap for EW stock: $61.83B
- P/E Ratio for EW stock: 43.504
Will EW's stock price go up? Is there an accurate EW stock forecast available?
TipRanks.com reports that Edwards Lifesciences currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $115.00. The target pricing ranges from a high EW forecast of $128.00 down to a low forecast of $90.00. Edwards Lifesciences (EW)’s last closing stock price was $99.45 which would put the average price target at 15.64% upside.
In addition, TradingView issued a Sell rating for EW stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EW stock.
Other analysts covering EW include:
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 118 on 4 days ago
- Adam Maeder of Piper Sandler issued a Buy rating with the price target of $ 120 on 4 days ago
- Jayson Bedford of Raymond James issued a Buy rating with the price target of $ 120 on 4 days ago
- Larry Biegelsen of Wells Fargo issued a Buy rating with the price target of $ 121 on 4 days ago
If you are wondering if EW is a good stock to buy, here are 3rd party ratings for EW stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Sell, Top 37% (93 out of 251)
What is the sentiment on the street regarding Edwards Lifesciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for EW stock: Bullish
- Blogger Consensus for EW stock: Bullish
- Media Buzz for EW stock: High
- Insider Signal for EW stock: Negative
- Investor Sentiment for EW stock: Neutral
- Hedge Fund signal for EW stock: Negative
The stock market is extremely volatile, and you need to do your own research on EW stock including scouring the social networks like EW StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EW stock chart >>
Summary: Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, congestive heart failure, orthopedics, complex wound care, geriatric surgical recovery, balance retraining, behavioral health and stroke recovery, as well as various rehabilitative programs. It provides hospice services to patients using an interdisciplinary care team comprising a physician, nurses, home health aides, social workers, therapists, dieticians, volunteers, counselors, chaplains and bereavement coordinators, when required. The company depends on reimbursement from Medicare (for chronic care) for a significant portion of its revenues on account of the age demographics of its patient base (average age of 81).
- Recent AMED Stock Price: $127.87
- Yearly Gain for AMED stock: -50.61%
- Market Cap for AMED stock: $4.17B
- P/E Ratio for AMED stock: 29.897
Will AMED's stock price go up? Is there an accurate AMED stock forecast available?
TipRanks.com reports that Amedisys currently has 13 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $144.85. The target pricing ranges from a high AMED forecast of $200.00 down to a low forecast of $95.00. Amedisys (AMED)’s last closing stock price was $127.87 which would put the average price target at 13.28% upside.
In addition, TradingView issued a Buy rating for AMED stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AMED stock.
Other analysts covering AMED include:
- John Ransom of Raymond James issued a Buy rating with the price target of $ 140 on 1 day ago
- Justin Bowers of Deutsche Bank issued a Buy rating with the price target of $ 175 on 2 days ago
- Michael Wiederhorn of Oppenheimer issued a Buy rating with the price target of $ 175 on 4 days ago
- Sarah James of Barclays issued a Buy rating with the price target of $ 154 on 4 days ago
If you are wondering if AMED is a good stock to buy, here are 3rd party ratings for AMED stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 40% (101 out of 251)
What is the sentiment on the street regarding Amedisys? (Current ratings compiled by TipRanks.com)
- News Sentiment for AMED stock: Neutral
- Blogger Consensus for AMED stock: Bearish
- Media Buzz for AMED stock: Very Low
- Insider Signal for AMED stock: ―
- Investor Sentiment for AMED stock: Neutral
- Hedge Fund signal for AMED stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on AMED stock including scouring the social networks like AMED StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AMED stock chart >>
Summary: AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
- Recent AZNCF Stock Price: $132.64
- Yearly Gain for AZNCF stock: 32.59%
- Market Cap for AZNCF stock: $203.36B
- P/E Ratio for AZNCF stock: -202.23
Will AZNCF's stock price go up? Is there an accurate AZNCF stock forecast available?
TipRanks.com reports that AstraZeneca currently has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $150.04. The target pricing ranges from a high AZNCF forecast of $207.48 down to a low forecast of $13.70. AstraZeneca (AZNCF)’s last closing stock price was $132.64 which would put the average price target at 13.12% upside.
In addition, TradingView issued a n/a rating for AZNCF stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AZNCF stock.
Other analysts covering AZNCF include:
- James Gordon of J.P. Morgan issued a Buy rating with the price target of $ 169.51 on 1 day ago
- Dominic Lunn of Credit Suisse issued a Buy rating with the price target of $ 134.83 on 1 day ago
- Carola Holtz of Kepler Capital issued a Hold rating with the price target of $ 142.39 on 4 days ago
- Luisa Hector of Berenberg Bank issued a Buy rating with the price target of $ 155.95 on 1 week ago
If you are wondering if AZNCF is a good stock to buy, here are 3rd party ratings for AZNCF stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding AstraZeneca? (Current ratings compiled by TipRanks.com)
- News Sentiment for AZNCF stock: Neutral
- Blogger Consensus for AZNCF stock: ―
- Media Buzz for AZNCF stock: Medium
- Insider Signal for AZNCF stock: Negative
- Investor Sentiment for AZNCF stock: ―
- Hedge Fund signal for AZNCF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on AZNCF stock including scouring the social networks like AZNCF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AZNCF stock chart >>
Summary: Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
- Recent RARE Stock Price: $50.63
- Yearly Gain for RARE stock: -37.37%
- Market Cap for RARE stock: $3.54B
- P/E Ratio for RARE stock: -6.922
Will RARE's stock price go up? Is there an accurate RARE stock forecast available?
TipRanks.com reports that Ultragenyx Pharmaceutical currently has 13 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $105.08. The target pricing ranges from a high RARE forecast of $146.00 down to a low forecast of $60.00. Ultragenyx Pharmaceutical (RARE)’s last closing stock price was $50.63 which would put the average price target at 107.54% upside.
In addition, TradingView issued a Sell rating for RARE stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RARE stock.
Other analysts covering RARE include:
- Cory Kasimov of J.P. Morgan issued a Buy rating with the price target of $ 128 on 4 days ago
- Gena Wang of Barclays issued a Buy rating with the price target of $ 105 on 4 days ago
- Dae Gon Ha of Stifel Nicolaus issued a Buy rating with the price target of $ 135 on 4 days ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $ 130 on 5 days ago
If you are wondering if RARE is a good stock to buy, here are 3rd party ratings for RARE stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 33% (82 out of 251)
What is the sentiment on the street regarding Ultragenyx Pharmaceutical? (Current ratings compiled by TipRanks.com)
- News Sentiment for RARE stock: Very Bearish
- Blogger Consensus for RARE stock: Neutral
- Media Buzz for RARE stock: Medium
- Insider Signal for RARE stock: ―
- Investor Sentiment for RARE stock: Very Positive
- Hedge Fund signal for RARE stock: Neutral
The stock market is extremely volatile, and you need to do your own research on RARE stock including scouring the social networks like RARE StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RARE stock chart >>
Summary: AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
- Recent ABBV Stock Price: $140.22
- Yearly Gain for ABBV stock: 26.43%
- Market Cap for ABBV stock: $247.78B
- P/E Ratio for ABBV stock: 20.289
Will ABBV's stock price go up? Is there an accurate ABBV stock forecast available?
TipRanks.com reports that AbbVie currently has 14 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $158.71. The target pricing ranges from a high ABBV forecast of $188.00 down to a low forecast of $135.00. AbbVie (ABBV)’s last closing stock price was $140.22 which would put the average price target at 14.78% upside.
In addition, TradingView issued a Sell rating for ABBV stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABBV stock.
Other analysts covering ABBV include:
- Carter Gould of Barclays issued a Hold rating with the price target of $ 160 on 1 day ago
- Steve Chesney of Atlantic Equities issued a Hold rating with the price target of $ 162 on 1 day ago
- Chris Schott of J.P. Morgan issued a Buy rating with the price target of $ 180 on 1 day ago
- Colin Bristow of UBS issued a Hold rating with the price target of $ 146 on 1 day ago
If you are wondering if ABBV is a good stock to buy, here are 3rd party ratings for ABBV stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 47% (133 out of 251)
What is the sentiment on the street regarding AbbVie? (Current ratings compiled by TipRanks.com)
- News Sentiment for ABBV stock: Very Bullish
- Blogger Consensus for ABBV stock: Bullish
- Media Buzz for ABBV stock: High
- Insider Signal for ABBV stock: ―
- Investor Sentiment for ABBV stock: Neutral
- Hedge Fund signal for ABBV stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ABBV stock including scouring the social networks like ABBV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ABBV stock chart >>
Summary: Teleflex is a global provider of medical technology products. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company markets and sells its products to hospitals and healthcare providers worldwide through a combination of direct sales force and distributors. Teleflex has manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States.
- Recent TFX Stock Price: $245.30
- Yearly Gain for TFX stock: -38.29%
- Market Cap for TFX stock: $11.50B
- P/E Ratio for TFX stock: 22.358
Will TFX's stock price go up? Is there an accurate TFX stock forecast available?
TipRanks.com reports that Teleflex currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $295.00. The target pricing ranges from a high TFX forecast of $370.00 down to a low forecast of $248.00. Teleflex (TFX)’s last closing stock price was $245.30 which would put the average price target at 20.26% upside.
In addition, TradingView issued a n/a rating for TFX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TFX stock.
Other analysts covering TFX include:
- Richard Newitter of Truist Financial issued a Hold rating with the price target of $ 265 on 4 days ago
- Chris Cooley of Stephens issued a Buy rating with the price target of $ 305 on 4 days ago
- Larry Biegelsen of Wells Fargo issued a Hold rating with the price target of $ 248 on 4 days ago
- Michael Matson of Needham issued a Buy rating with the price target of $ 291 on 4 days ago
If you are wondering if TFX is a good stock to buy, here are 3rd party ratings for TFX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 37% (93 out of 251)
What is the sentiment on the street regarding Teleflex? (Current ratings compiled by TipRanks.com)
- News Sentiment for TFX stock: Very Bullish
- Blogger Consensus for TFX stock: Bullish
- Media Buzz for TFX stock: Very High
- Insider Signal for TFX stock: Negative
- Investor Sentiment for TFX stock: Very Negative
- Hedge Fund signal for TFX stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on TFX stock including scouring the social networks like TFX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TFX stock chart >>
Summary: Community Health Systems, Inc. is a leading operator of general acute care hospitals and outpatient facilities in communities across the U.S. Its hospitals are general care hospitals offering a wide range of inpatient and outpatient medical services like general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric and rehabilitation services. Some of its hospitals provide skilled nursing and home care services based on individual community needs. Community Health provides outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The company generates revenues through general and specialized hospital healthcare services and outpatient services to patients in the communities. The healthcare provider pursues a portfolio rationalization and deleveraging strategy as a result of which it continues to divest hospitals and non-hospital businesses.
- Recent CYH Stock Price: $3.03
- Yearly Gain for CYH stock: -77.05%
- Market Cap for CYH stock: $408.12M
- P/E Ratio for CYH stock: -8.739
Will CYH's stock price go up? Is there an accurate CYH stock forecast available?
TipRanks.com reports that Community Health currently has 8 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.63. The target pricing ranges from a high CYH forecast of $9.00 down to a low forecast of $3.50. Community Health (CYH)’s last closing stock price was $3.03 which would put the average price target at 95.38% upside.
In addition, TradingView issued a Sell rating for CYH stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYH stock.
Other analysts covering CYH include:
- Michael Wiederhorn of Oppenheimer issued a Buy rating with the price target of $ 6 on 4 days ago
- David S Macdonald of Truist Financial issued a Hold rating with the price target of $ 3.5 on 4 days ago
- Ben Hendrix of RBC Capital issued a Buy rating with the price target of $ 9 on 5 days ago
- Joseph France of Loop Capital Markets issued a Hold rating with the price target of $ 5 on 1 month ago
If you are wondering if CYH is a good stock to buy, here are 3rd party ratings for CYH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Bottom 24% (192 out of 251)
What is the sentiment on the street regarding Community Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for CYH stock: Very Bearish
- Blogger Consensus for CYH stock: Bullish
- Media Buzz for CYH stock: Very High
- Insider Signal for CYH stock: Positive
- Investor Sentiment for CYH stock: Very Positive
- Hedge Fund signal for CYH stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CYH stock including scouring the social networks like CYH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CYH stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================